Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes mellitus (T2DM). Fixed-dose combinations of alogliptin with both metformin and pioglitazone are also commercially available, providing a measure of convenien...

Descripción completa

Detalles Bibliográficos
Autores principales: Holland, Daniel Q, Neumiller, Joshua J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090041/
https://www.ncbi.nlm.nih.gov/pubmed/25050071
http://dx.doi.org/10.2147/DMSO.S37648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090041/
https://www.ncbi.nlm.nih.gov/pubmed/25050071
http://dx.doi.org/10.2147/DMSO.S37648

Ejemplares similares